 
 
Clinimark  
[ADDRESS_1001187]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   1   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
CLINIMARK Clinical Investigation Plan  
 
Vital [LOCATION_003] Respi[INVESTIGATOR_732761] 201 9-326 
 
COMMERCIAL SPONSOR:  
Vital  [LOCATION_003], [ADDRESS_1001188] Palm Beach, FL [ZIP_CODE]  
   
Document 
Ownership:  Document is in accordance with Code of Federal Regulations for Non -Significant Risk Investigations and 
ISO [ZIP_CODE]  where applicable  
Function, Title  Name  [CONTACT_164300],  Laboratory 
Manager  Roger Martin -
Pressman  
 26 APR 201 9 
Clinimark, Associate 
Researcher  Carolyn Cohen  
 26 APR 2019  
 
Document 
Approver:  The document approvers are listed below:  
Function, Title  Name  [CONTACT_164300], Chief Clinical 
Officer  Paul Batchelder  
 26 APR 2019  
Clinimark, Chief 
Technical Officer  Dena M. Raley  
 26 APR 2019  
Vital [LOCATION_003], Chief 
Technology  Officer  Mark Khachaturian     
 
Revision 
History:  
Revision  Date  Revision Description  
Version 1  26 APR 2019  Original issue  
   
 Author:   Roger Martin -Pressman  
  Laboratory Manager  
CLINIMARK, Laboratories  
Avista Adventist Hospi[INVESTIGATOR_164261]  
[ADDRESS_1001189]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   2   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Vital [LOCATION_003] Respi[INVESTIGATOR_732761] 201 9-326 
 
ETHICS COMMITTEE REVIEW:  
Salus Institutional Review Board  
[ADDRESS_1001190] Austin, TX [ZIP_CODE]  
John C. Lewis, DVM: Chairman Board 1  
Charles F. Ryan, PhD, RPh:  Vice -Chair Board 1  
Patricia L. Gonzales , PharmD : Chairman Board 2   
Frederick N. Kopec, JD: Vice -Chair Board 2  
Alex ander Kenaston, RN, MS, PhD, CIP: Chairman Board 3  
 
STUDY PROCEDURE:   
Vital [LOCATION_003] Respi[INVESTIGATOR_13581] V alidation in Adults  
Clinimark Study ID# PR 2019 -326 
 
COMMERCIAL SPONSOR:  
        Vital [LOCATION_003], [ADDRESS_1001191] Palm Beach, FL [ZIP_CODE]  
 
PRINCIPAL INVESTIGATOR:   
[INVESTIGATOR_136170] , MD.  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_1001192], Golden,  Colorado [ZIP_CODE]  
 
MEDICAL OVERSIGHT:  
Arthur Cabrera, MD.  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_1001193]  
Louisville, CO [ZIP_CODE]  
 
STUDY SITE:  
Clinimark,  Site ID# [ADDRESS_1001194]  
Louisville, CO [ZIP_CODE]  
 
CONFIDENTIALITY:  
The information contained in this document is confidential and is intended for the use of Clinical Investigators.  It 
will not be copi[INVESTIGATOR_732762] C linical Investigations of Vital [LOCATION_003],  unless such 
persons are bound by a confidentiality agreement with Clinimark or Vital [LOCATION_003].  
 
 
Clinimark  
[ADDRESS_1001195]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   3   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Vital [LOCATION_003] Respi[INVESTIGATOR_732761] 201 9-326 
Summary  
Introduction  
Vital [LOCATION_003] is dedicated to developi[INVESTIGATOR_732763]. Vital [LOCATION_003] is a manufacturer of a multi -parameter patient monitor  that is intended to be  
used in a variety of medical settings including hospi[INVESTIGATOR_600], medical offices and patients’ homes.  
 
Objectives of the Clinical Investigation Plan  
The purpose of this study is to conduct a Respi[INVESTIGATOR_732764] m onitor Reference Standard (GE Datex -Ohmeda).   
 
Background  
Respi[INVESTIGATOR_732765]. End Tidal 
Carbon Dioxide (EtCO 2)  is considered to be the highest level of safety and accuracy in Respi[INVESTIGATOR_732766].  
 
The medical device studied under this protocol will be the non- invasive  and investigational Vital [LOCATION_003], Vital Detect .  
The Vital Detect uses multiple sensors in a portable  device to measure a wide array of patient parameters.  
Respi[INVESTIGATOR_732767]  a combination of sensors of the Vital Detect.  
 
Clinical testing of this device will occur only after bench testing and safety testing ha ve been completed at Vital 
[LOCATION_003]. 
 
Protocol  Overview  
After IRB Approva l, a minimum of [ADDRESS_1001196]  (Device Under Test).  The 
subjects will be selected to represent a range of body types including small, average, muscular, and large with a 
range of BMIs.  
 
Each subject will be connected to a F DA cleared EtCO 2 monitor (GE Datex -Ohmeda ) and will be  instrum ented with 
a mouthpi[INVESTIGATOR_732768] [ADDRESS_1001197]  with the use of a paced breathing 
application on a mobile phone .  The rates will be approximately 5, 10, 15, 20, 25, 30, 35, 40, 45,  and 5 0 breaths per 
minute; with some natural variation from these exact numbers and tailored to the subject’s capabilities as some 
subjects may not be able to breathe at the lower and hi gher respi[INVESTIGATOR_119068].   
 
The respi[INVESTIGATOR_732769].  
 
For the data analysis, the EtCO 2 monitor will be used to assess the stability of the data. If the respi[INVESTIGATOR_732770], then the data for that period will be 
considered unstable and removed from analysis.  
 
To ‘P ass’ this test the Vital [LOCATION_003], Vital Detect  must demonstrate a respi[INVESTIGATOR_697] A RMS of ≤3 when compared to the 
Reference EtCO 2 monitor  over the range of 5 to 45 breaths per minute.  An additional goal would be for the A RMS to 
be ≤[ADDRESS_1001198]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   4   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Study Population  
The study population will include [ADDRESS_1001199] be healthy showing no evidence of 
medical problems as indicated by [CONTACT_732802]. Eligible subjects need to meet all of the inclusion criteria and none of the exclusion criteria for 
participation.  
 
Inclusion Criteria  
• Subject must have the ability to understand and provide written informed consent  
• Subject is adult over 18 years of age  
• Subject must be willing and able to comp ly with study procedures and duration  
• Subject is a non- smoker  
• Male or female of any race 
 
Exclusion Criteria  
        Subjects who meet any of the following criteria will be excluded from the study:  
• Subject is considered as being morbidly obese (defined as  BMI >39.5)  
• Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull 
or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain 
malformations may still allow subje cts to participate if the condition is noted and would not affect the 
particular sites utilized.)  
• Subjects with known respi[INVESTIGATOR_136172]:  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortness of breath / respi[INVESTIGATOR_1506],  
o respi[INVESTIGATOR_545486],  
o emphysema, COPD, lung disease  
• Subjects with self- reported heart or cardiovascular conditions such as:  
o have had cardiovascular surgery 
o Chest pain (angina)  
o heart rhythms other than a  normal sinus rhythm or with respi[INVESTIGATOR_25570]  
o previous heart attack  
o blocked artery  
o unexplained shortness of breath 
o congestive heart failure (CHF)  
o history of stroke  
o transient ischemic attack  
o carotid artery disease  
o myocardial ischemia  
o myocardial  infarction  
o cardiomyopathy  
• Self-reported health conditions as identified in the Health Assessment Form  
o diabetes,  
o uncontrolled thyroid disease,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood febrile seizures),  
o epi[INVESTIGATOR_002],  
 
 
Clinimark  
[ADDRESS_1001200]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   5   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
o history of unexplained syncope,  
o recent history of frequent migraine headaches,  
o recent head injury within the last 2 months,  
o Cancer / chemotherapy 
• Other known health condition, should be considered upon disclosure in health assessment form  
 
It is expected that the data collection will take  approximately  4-[ADDRESS_1001201]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   6   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Vital [LOCATION_003] Respi[INVESTIGATOR_732771] 201 9-326  
 
Table of Contents  
Summary  ........................................................................................................................................................................ 3 
Introduction  ............................................................................................................................................................... 3 
Objectives of the Clinical Investigation Plan  .............................................................................................................. 3 
Background  ................................................................................................................................................................ 3 
Protocol Overview  ..................................................................................................................................................... 3 
Study Population  ....................................................................................................................................................... 4 
Inclusion Criteria  .................................................................................................................................................... 4 
Exclusion Criteria  ................................................................................................................................................... 4 
Table of Contents  .......................................................................................................................................................... 6 
Identification and Description of the Investigational Device  ........................................................................................ 9 
Data Acquisition System for the Investigational Device  .......................................................................................... 10 
Safety Equipment  .................................................................................................................................................... 10 
Preliminary Investigat ions and Justifications of the Study  ...................................................................................... 10 
Risks and Benefits of the Investigational Device and Clinical Investigation  ................................................................ 10 
ECG Electrodes  ......................................................................................................................................................... 11 
Pulse Oximetry  Sensor  ............................................................................................................................................. 11 
Benefits  .................................................................................................................................................................... 11 
Design of the Clinical Investi gation  .............................................................................................................................. 11 
Method  .................................................................................................................................................................... 11 
Equipment  ............................................................................................................................................................... 12 
Study Population  ..................................................................................................................................................... 12 
Inclusion Criteria  .................................................................................................................................................. 13 
Exclusion Criteria  ................................................................................................................................................. 13 
Duration of Clinical Investigation ............................................................................................................................. 14 
Criteria for Study Termination  .................................................................................................................................  14 
Procedure  .................................................................................................................................................................... 14 
Statistical Analysis  ....................................................................................................................................................... 15 
Endpoint / Comparator  ............................................................................................................................................ [ADDRESS_1001202] (IRB)/Independent Ethics Committee (IEC)  .................................................................. [ADDRESS_1001203]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   7   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Data and Quality Management / Confidentiality  .................................................................................................... 16 
Records - Study Documentation / Case Report Forms  ............................................................................................ [ADDRESS_1001204] Documents  .................................................................................................................................................. 17 
Data Collection Forms / Case Report Forms  ............................................................................................................ [ADDRESS_1001205]  .................................................................................................................................................................  20 
Adverse Event Definitions .................................................................................................................................... 20 
Management of Adverse Event Reporting  .............................................................................................................. 21 
Reporting of Serious Adverse Events and / or UADE  ............................................................................................... 21 
Vital [LOCATION_003] Records and Reports  ................................................................................................................................ 21 
Records 21 CFR 812.140 (b) 4,5 ........................................................................................................................... 21 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  ................................................................................................ [ADDRESS_1001206]  .................................................................................................................. 22 
Withdrawal of IRB approval  .................................................................................................................................  22 
Withdrawal if FDA approval  .................................................................................................................................  22 
Progress Reports  .................................................................................................................................................. 22 
Recall and device  ................................................................................................................................................. 22 
Final Report  ......................................................................................................................................................... 22 
Informed consent  ................................................................................................................................................ 22 
Significant risk device determinations –  (does not apply to NSR studies)  ........................................................... 22 
Other  .................................................................................................................................................................... 22 
Investigators Records and Reporting ....................................................................................................................... 22 
Records 21 CFR 812.140 (a)(3)(i)  ......................................................................................................................... 22 
Reports 21 CFR 812.150 (a) 1,2,5,[ADDRESS_1001207]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   8   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Informed consent  ................................................................................................................................................ [ADDRESS_1001208]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   9   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Vital [LOCATION_003] Respi[INVESTIGATOR_732772] [ADDRESS_1001209] respi[INVESTIGATOR_696] r ate will be evaluated during non- motion conditions 
over the range a range of 5 -50 breaths per minute via Reference EtCO 2.  
 
A FDA cleared, GE Healthcare S5 Multi -parameter monitoring system with End Tidal Carbon Dioxide (EtCO 2) will be 
used for the Respi[INVESTIGATOR_732773]. There are no risks or adverse device effects to be assessed. There are no 
contraindications for use in the proposed study / study population.  
 
 
Identification and Description of the Investigational Device  
The Vital  Detect is a non -invasive device designed for spot -checking physiological parameters, such as Non - 
Invasive Blood Pressure (NIBP), Oxygen Saturation (SpO 2), Pulse Rate (PR), Body Temperature (TEMP) and 
Respi[INVESTIGATOR_13581] (RR). This device is a finger -cuff technology which is applicable for use at -home use or in 
healthcare facilities in/on individuals [ADDRESS_1001210] analyzes the data collected during the NIBP and SpO 2 
measurement cycles to determine the user’s respi[INVESTIGATOR_12463]. The pulse oximeter being used in this study collects data from the finger by [CONTACT_545497](s) through tissue to 
measure respi[INVESTIGATOR_1487].  The Vital Detect pulse oximetry system is investigational and has not been cleared by 
[CONTACT_1622].  
 
The intended purpose of the device under test is spot -checking, non -invasive monitoring / logging of respi[INVESTIGATOR_732774]. For this evaluation, the device will be run in a continuous data collection mode.  
 
The manufacturer of the investigational device followed the good manufac turing practice regulation of 21 CFR 820 
as appropriate.  
 
 
Figure 1  – Vital Detect  the Device Under Test  

 
 
Clinimark  
[ADDRESS_1001211]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   10   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
All appropriate testing to  demonstrate safety for use in human studies was completed prior to Clinimark’s receipt 
of the device. Such documentation will reside in the design history files of the Sponsor. Documentation will be 
provided regarding the safety of the investigational device for electrical current , dielectric strength, surface 
temperatures and biocompatibility testing . The manufacturer of the investigational devices followed the FCC 
licensing requirements for product builds . 
 Instructions for installation, use, storage and handling can be found in the Device Operator’s Manual and or 
Instructions for Use. Device model numbers, software version, serial numbers, date(s) of use, subject ID number(s) 
will be recorded in the study documentation.   
 
Data Acquisition System for the Investigational Device 
The data from t he Device Under Test  will be collected on an a pplication installed on the iOS or Android mobile 
device  separate from the  reference equipment .   
 
Safety Equipment  
Multi -parameter monitor used during the study to observe a subject’s vital signs include  ECG tracing, heart ra te, 
respi[INVESTIGATOR_697],  and EtCO 2 with capnograph.  
• GE Healthcare S5 Compact Monitor, M -NEST PR module with ECG, and/or Multi -parameter monitor  
• Portable oxygen tank, mask and ambu bag  
• GE Healthcare (Datex -Ohmeda) 3900 TruTrak+ / OxyTip+ Oxy -F-UN or Oxy -AF Sensor and Oxy -OL3 cable 
(SpO 2 monitoring)  
• Blood pressure cuff and stethoscope  
 
Preliminary Investigations and Justifications of the Study  
This will be the first clinical study conducted at Clinimark a s part of the development of the Vital [LOCATION_003], Vita l Detect 
respi[INVESTIGATOR_732775] . 
Risks and Benefits of the Investigational De vice and Clinical Investigation  
Currently the FDA defines respi[INVESTIGATOR_732776]. The Device Under Test in this study is  
considered non -significant risk device.  
 
The device and use of the Device Under Test does not meet the definition of significant risk device under 21 CFR 
812.3(m) .  For the purpose of this study:  
• It is not intended as an implant.  
o Sensors are applied to t he surface of the site and are removed following data collection typi[INVESTIGATOR_348534] 1 day.  
o Adhesive ECG electrodes for health screening and monitoring may cause some skin irritations.  
• It is not purported or represented to be for use in supporting or sust aining human life, nor does it present 
a potential for serious risk to the health, safety, or welfare of a subject.  
o Monitors and are not used to support or sustain human life.  
• It is not for use of substantial importance in diagnosing, curing, mitigating,  or treating disease, or 
otherwise preventing impairment of human health .  
o Monitors are Class II devices used to  measure respi[INVESTIGATOR_697] . They are not used to diagnose, 
cure, mitigate, or treat disease. These devices are typi[INVESTIGATOR_348535] a general indication for 
non-invasive measurement of respi[INVESTIGATOR_697] . 
• The device as used in this investigation does not present a serious risk to the  health, safety, or welfare of 
a subject.  
o See below for discussion of risk associated with the device and use of the device.  
 
 
 
Clinimark  
[ADDRESS_1001212]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   11   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
There are no anticipated risks or adverse device effects to be assessed. There are no contraindications for use in 
the proposed st udy / study population. There may be other risks to the subject associated with the device or 
procedure that are unforeseeable at this time.  
 
ECG Electrodes  
Materials (such as the adhesive and/or gel contact) used in the electrodes may cause some skin irritations in some subjects. Typi[INVESTIGATOR_548060]. 
Biocompatibility te sting for surface contact [CONTACT_164283] a requirement of the International Organization of 
Standardization  (ISO) [ZIP_CODE] –  Biological Evaluation of Medical Devices. The risk in the use of ECG electrodes is 
believed to be minimal.  
 
Pulse Oximetry Sensor  
Pulse  Oximetry Sensor placement involves positioning pulse oximetry sensors on the volunteer subject in the same 
manner that is used on hospi[INVESTIGATOR_9643].  The sensors may be warm to the touch. Under normal operating 
conditions, no fault conditions, the sensors are not expected to overheat. If the sensors are too warm, they will be 
removed immediately.  Clip on and soft reusable sensors exert a minimal amount of pressure. They should not cause discomfort. Adhesive sensors or tape may cause some irritations t o the skin in some subjects. Every effort 
will be made to minimize products with natural rubber or latex. Products containing natural rubber or latex will be 
identified.  The risk in the use of pulse oximetry sensors is believed to be minimal
. 
 
Benefits  
The benefits to the study are to the advancement of non -invasive medical monitoring of patients by [CONTACT_164284]. There are no direct benefits to the subjects participating in this study 
other than being a paid volunteer.  The only alternative to this study is to NOT participate.  
 
Design of the Clinical Investigation  
 
Method 
This study is a comparative, single -center, non -randomized study in a minimum of [ADDRESS_1001213] (GE Datex -Ohmeda).   
 
The procedures will be explained to the volunteer test subject and an Informed Cons ent will be signed by [CONTACT_1560]. A health form and health screening will be conducted prior to the start of the test.  Subjects will be seated 
to apply the devices and take baseline data, as well as the remainder of the study.    
For the respi[INVESTIGATOR_732777] a mouthpi[INVESTIGATOR_730193] a monitoring 
line allowing for measurement of the EtCO
2 derived respi[INVESTIGATOR_697]. Nose plugs/clips will be used so the subject 
can only breath through the mouthpi[INVESTIGATOR_13959]. The subject is able to take out the mouthpi[INVESTIGATOR_732778].  
 
A GE Healthcare Datex -Ohmeda S/[ADDRESS_1001214].  The rates will be 
approximately 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 BPM; with some natural variation from these exact numbers and tailored to the subject’s capabi lities as some subjects may not be able to breathe at the lower and higher 
 
 
Clinimark  
[ADDRESS_1001215]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   12   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
respi[INVESTIGATOR_119068]. The subject will follow a paced breathing app.  Once stable breathing at specified rate is 
achieved, data will be collected for one and a half to three minutes. I f the respi[INVESTIGATOR_732779], then the data for that period will be considered unstable.  
 After s tarting with a stable respi[INVESTIGATOR_732780]’s  natural rate  (without the breathing app) , the breathing 
pattern on the app will be set to begin near the natural respi[INVESTIGATOR_732781] t and continue to go down by 
[CONTACT_732803][INVESTIGATOR_732782] [ADDRESS_1001216]’s natural respi[INVESTIGATOR_732783] [ADDRESS_1001217] development /training by [CONTACT_456].  
 
Equipment  
The software collects the R eference and acceptance data at 1 second intervals and allows for marking events.  
 
Description of Clinimark Gas Mixing Fixture with Automated Data Collection:  
 Computer with gas mixing/control software and automated data collection system  
 Sealink Mux box –  8 channel, communication cables  
 Gas control fixture (not used to deliver gas in this study but needed to run the software)  
 
Safety Equipment  
GE Healthcare Datex -Ohmeda S/5 Multi -parameter Monitor, M -NESTPR module with ECG , M-COVX 
module – Spi[INVESTIGATOR_732784] (Datex -Ohmeda) 3900 TruTrak+ / OxyTip+ Oxy -F-UN Sensor and Oxy- OL3 cable  
Portable oxygen tank, mask and ambu bag  
 Blood pressure cuff and stethoscope  
 
Supplies for Subject  
Ventilation tubing and open system mask  
Mouthpi[INVESTIGATOR_732785] 2 sample line  
Reference – Respi[INVESTIGATOR_732786] -Ohmeda  S/5 Multi -parameter Monitor, M -NESTPR module with ECG , 
M-COVX module – Spi[INVESTIGATOR_038] (K021279) (Reference EtCO 2) 
 
Investigational Device  
Vital [LOCATION_003], Vital Detect  
  
There are no deviations expected from this investigation plan. Should deviations be needed, discussi ons will be 
conducted with Vital [LOCATION_003] and Principal Investigator  [INVESTIGATOR_732787].  
 
Study Population  
The study population will include [ADDRESS_1001218]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   13   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
screening. Eligible subjects needed to meet all of the inclusion criteria and none of the exclusion criteria for 
participation.  
 
Inclusion Criteria  
• Subject must have the ability to understand and provide written informed consent  
• Subject is adult over 18 years of age  
• Subject must be willing and able to comply with study procedures and duration  
• Subject is a non- smoker  
• Male or female of any race 
 
Exclusion Criteria  
        Subjects who meet any of the following criteria will be excluded from the study : 
• Subject is considered as being morbidly obese (defined as BMI >39.5)  
• Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull 
or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain 
malformations may still allow subjects to parti cipate if the condition is noted and would not affect the 
particular sites utilized.)  
• Subjects with known respi[INVESTIGATOR_136172]:  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortness of breath / respi[INVESTIGATOR_1506],  
o respi[INVESTIGATOR_732788],  
o emphysema, COPD, lung disease  
• Subjects with self- reported heart or cardiovascular conditions such as:  
o have had cardiovascular surgery 
o Chest pain (angina)  
o heart rhythms other than a normal sinus rhythm or with respi[INVESTIGATOR_25570]  
o previous heart attack  
o blocked artery  
o unexplained shortness of breath 
o congestive heart failure (CHF)  
o history of stroke  
o transient ischemic attack  
o carotid artery disease  
o myoc ardial ischemia  
o myocardial infarction  
o cardiomyopathy  
• Self-reported health conditions as identified in the Health Assessment Form  
o diabetes,  
o uncontrolled thyroid disease,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood fe brile seizures),  
o epi[INVESTIGATOR_002],  
o history of unexplained syncope,  
o recent history of frequent migraine headaches,  
o recent head injury within the last 2 months,  
o Cancer / chemotherapy 
• Other known health condition, should be considered upon disclosure in health assessment form  
 
 
 
Clinimark  
[ADDRESS_1001219]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   14   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Duration of Clinical Investigation  
Each subject, and therefore use of the device, is expected to take approximately [ADDRESS_1001220] population.  
 
Criteria for Study Terminat ion 
The study will be terminated if any of the following conditions occurs:  
• The subject may stop the study for any reason without prejudice  
• Development of any cardiac arrhythmia, except sinus arrhythmia <120 bpm  
• Sustained sinus tachycardia ≥120 bpm  
• Onset of PVCs  
 Any data collected to the point of a decision to terminate the study will be reviewed for inclusion to the analysis 
prior to generation of the final results. Data excluded from the analysis will be documented with justifications.  
 
Procedure  
1. Complete equipment setup and checkout prior to starting study.  
2. Set and / or synchronize the com puter clocks for Vital [LOCATION_003] and Clinimark data collection systems  
3. Explain the procedure to the subject. Have them read the Informed Consent Form, and review the information answering all questions. Once all questions have been answered, have the subject sign and 
date the Informed Consent Form. Have the subject complete, sign and date the Health Assessment Form. 
Each subject will be given a copy of the consent form prior to release.  
4. The clinician or PI [INVESTIGATOR_732789].  
5. Apply ECG leads to the subject, review for normal sinus rhythm or sinus arrhythmia.  
6. Record all baseline vital signs (SpO
2, Pulse Rate/ Heart Rate, ECG rhythm,  Respi[INVESTIGATOR_13581],  Antecubital 
fossa check and alcohol smell check).  
7. Based on the responses  to the h ealth assessment form and verbal health assessment, record accepted or 
declined from the study. Continue if accepted into the study.  
8. Setup and verify communication between the devices and data collection systems.  
9. Record device information for trac king (manufacturer, model #, serial/lot, hardware/software control 
info).  
10. Record subject information. Subject number and demographics information for subject description.  
11. Apply Device Under Test  sensors to the subject. Adjust sensors as appropriate and re cord on test form.  
12. Instruct the subject how to use the mouthpi[INVESTIGATOR_13959].  Starting data collection, the subject is instructed to 
breathe at their natural rate (without the breathing app) for a baseline data set.  
13. A range of stable respi[INVESTIGATOR_732790] a paced 
breathing app. The rates will be approximately 5, 10, 15, 20, 25, 30, 35, 40, 45 and 50 breaths per minute; 
with some natural variation from these exact numbers  and tailored to the subject’s abilities. Once  a stable 
breathing at specified rate is achieved data will be collected for one and a half to three minutes.  
a. The breathing pattern on the app will be set to begin near the normal Respi[INVESTIGATOR_732791] (baseline) and continue to go down by [CONTACT_732804][INVESTIGATOR_732792] [ADDRESS_1001221]’s normal 
Respi[INVESTIGATOR_732793] [ADDRESS_1001222] can 
tolerate comfortably . 
14. The respi[INVESTIGATOR_732794]
2 
(Reference) and the Device Under Test. Record any a dditional study notes that describe conditions of the 
test as well as deviations  and device issues . 
15. End the data collection and t ake all equipment off.  
  
 
 
Clinimark  
[ADDRESS_1001223]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   15   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Statistical Analysis  
Statistical Analysis will be performed by [CONTACT_348560].  
 
The Reference Respi[INVESTIGATOR_732795] [ADDRESS_1001224] able and 
removed from analysis.   The final pairing to be analyzed is the average of the 20 second periods of the Reference 
EtCO 2 with the average of the simultaneous 20 second period for the DUT. T he Accuracy root -mean -square (Arms)  
will be the basis for evaluation and acceptance.  
 
Endpoint / Comparator  
The primary objective of this study is to compare the accuracy of the Device Under Test for the measurement of 
respi[INVESTIGATOR_348541], which is an End Tidal Carbon Dioxide  Monitor (EtCO 2). Twenty second periods 
will be averaged to provide one respi[INVESTIGATOR_732796]. Each stable respi[INVESTIGATOR_732797] A RMS calculation.   
 The endpoint of inte rest is accuracy as measured by [CONTACT_348558] -mean -square (Arms) difference between 
the Device Under Test (DUT) and the Reference EtCO
2 (Ref) for all stable respi[INVESTIGATOR_732798]:   
 
 
 
Acceptance Criteria: Passing requires an Arms of < 3 with a goal of achieving 2.  
 
Sample Size Justification  
The Pulse Oximetry FDA Guidance Document (March 4, 2013, Section 4.1. 1 In vivo testing for SpO2 accuracy under 
laboratory conditions ) calls for [ADDRESS_1001225], providing > [ADDRESS_1001226] (IRB)/Independent Ethics Committee (IEC)  
Prior to the start of subject enrollment, the Primary I nvestigator will be responsible for obtaining approval from 
the authorized IRB/IEC for the institution at which the proposed clinical investigation is to be conducted. Written 
approval from the IRB/IEC should specifically refer to the I nvestigator, the pro tocol title and date, and subject 
informed consent date.  Written IRB/IEC approval and any conditions of approval imposed by [CONTACT_1201]/IEC will be 
obtained by [CONTACT_941] I nvestigator.  
 
Protocol amendments must also undergo IRB/IEC review and approval at each clinica l site. The written approval 
from the IRB/IEC for the amendment should specifically refer to the I nvestigator, the protocol version number and 
title, and any amendment numbers that are applicable.  
 
Monitoring Arrangements  
Vital [LOCATION_003] or Clinimark personnel  (Louisville, C O, [LOCATION_003] ) will provide all monitoring. The Monitor shall be responsible 
for maintaining a record of the findings, conclusions, and actions taken for the results of monitoring the study 
ensuring that:  
 

 
 
Clinimark  
[ADDRESS_1001227]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   16   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
The monitoring requirements for an  NSR device study is identified in 21 CFR 812.2(b) Abbreviated requirements. 
For monitoring a n NSR device investigation, the requirement is to comply with [ADDRESS_1001228] to 
monitoring investigations: (a) Securing Compliance, (b) Unanticipated adverse device effects, (c) Resumption of 
terminated studies  
• Compliance to the signed agreement between the Investigator and Vital [LOCATION_003] 
• The study follows the protocol and any amendments that apply  
• Compliance to any conditions of the approval imposed by [CONTACT_164287]:  
• The conditions for the study conti nue to be acceptable  
• Accurate, complete, and current records are maintained and required reports are written  
• Any adverse effects are documented and reported to Vital [LOCATION_003] and IRB as appropriate  
• Monitor activities may include for example:  performing source data verification and requesting 
corrections to feedback forms where potential inconsistencies or missing values are identified  
• Findings of non- compliance or required modifications are reviewed with the I nvestigator and Vital [LOCATION_003], 
and is presented in a wri tten report to both  
• Providing a Monitoring Report at the end of the Clinical Investigation  
 
Monitoring Plan  
1) Informed Consent  
• Verify that the consent form was signed prior to any study procedures being conducted  
• Verify that the staff conducting the consent is listed for approval on the Delegation of Authority Log  
• Ensure that the consent process is documented 
2) Subject Eligibility  
• Verify that the subject meets the inclusion criteria and none of the exclusion criteri a 
3) Baseline Data  
• Verify demographic informati on with the health assessment form  
• Check that informed consent time and date is prior to start of the procedure  
4) Verify all CRFs are completed  
5) Adverse Events  
• Verify that Adverse Events and Serious Adverse Events / UADEs are being reported accordingly to the 
IRB and Vital [LOCATION_003] in the required timeframe  
6) Protocol Deviations  
• Verity that Protocol Deviations are being reported accordingly to the IRB and Vital [LOCATION_003] in the 
required timeframe  
7) Electronic Data Review  
• Verify that the filename [CONTACT_732810]  
8) Ensure the Trial Master File is complete  
 
 
Data and Quality Management / Confidentiality  
A checklist will be maintained identifying the contents of the Trial Master File / Project folder PFC# [ADDRESS_1001229]’s name [CONTACT_120254] s will be recorded on the Informed Consent, Health Assessment Form, and a 
subject  screening and enrollment logs . The data collection form will only use a subject number and initials for the 
day of the test along with subject demographics. A name [CONTACT_164305].  
 Records identifying the subject’s name [CONTACT_732811] a secured location with either a locked file or locked door.  
Access to these files will be on a limited basis. Potential reviewers of this information include: Clinimark 
 
 
Clinimark  
[ADDRESS_1001230]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   17   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
representatives collecting the information and conducting the study, Medi cal Director for Clinimark, the U.S. Food 
and Drug Administration (FDA), Department of Health and Human Services (DHHS) agencies, Governmental 
agencies in other countries, Salus Independent  Review Board and representatives of the Sponsor. This group may 
use the information to conduct independent audits and reviews to verify compliance of the regulatory 
requirements for these studies but not copy the information.   
Data files stored electronically will be associated with a subject based off subject #, date a nd by [CONTACT_732805]. The  device ’s electronic data files will be preserved in its original form. Data analysis 
will be performed as a separate electronic file.    
Data files, data collection records with subject demographics  and subject number may be additionally copi[INVESTIGATOR_530], 
(after de -identification, if applicable) reviewed and supplied to the commercial sponsor for the study or 
Contractors associated with Clinimark for data analysis purposes.  
 
All study records will be stored fo r at least [ADDRESS_1001231] igator.  
 
Records - Study Documentation / Case Report Forms  
Sponsor  Respi[INVESTIGATOR_732799]# PR [ADDRESS_1001232] Documents  
Provided as separate documents to this protocol : 
• Informed Consent form (IRB approved)  
• Health Assessment Form (Clinimark Control # F2000 -001-001 Rev 13 or current revision ) 
 Study Conduct Documents : 
• CRF2019 -326 – Case Report  Forms  
• Electronic Files –  electronic data collected from the Refence and Device Under Test  
 
Data Collection Forms / Case Report Forms  
To ensure the quality and integrity of the data, it is the responsibility of the Investigator(s) or designee to complete 
the Case Report Forms (CRFs) for each subject who is enrolled to participate in this study.  In some cases,  the data 
collection forms will also be the source document for some information that is not directly collected in the Health 
Assessment Form. The following information will be recorded on the site’s data collection forms ( CRF): 
• Study date, Subject ID#, Subject Initi als, and Relevant Subject Demographics, Associated Electronic 
Filename(s)  
• Evidence that informed consent was signed and dated prior to the subject participating in the study  
• Information for Subject Inclusion or Exclusion to the study  
• Equipment calibration and communication check out  
• Device usage / sensor placement on the subject  
• Baseline SpO 2 and pulse rate  
• Annotations on data point markers, stability, and other observations used in the data analysis  
• Protocol deviation reporting  (only if needed)  
• Adverse Ev ents reporting  (only if needed)  
• Study termination  
 
 
 
Clinimark  
[ADDRESS_1001233]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   18   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
A black or blue pen will be used to record data on the data collection forms. Recorded information should be 
legible and completed. Erroneous entries should be crossed out, corrected with the change, initialed and dated by 
[CONTACT_732806]. The Investigator(s) or designee will sign and date at indicated places on each 
page of the data collection form. The Protocol Deviations Reporting can be signed and dated by [CONTACT_348563], otherwise the Sub -Investigator or Investigator should review, sign and date. The Adverse 
Events Reporting should be signed and dated by [CONTACT_164289] a Sub- Investigator or Investigator. The Principal 
Investigator [INVESTIGATOR_348549], sign and date all serious adverse events.  The Investi gator or designee will provide a 
final signature [CONTACT_164306] a thorough inspection of all subject data has been performed and will thereby [CONTACT_164290]. The Investigator’s Certification Statement will disclose the overall documenta tion, study 
oversight and certification of the study.   
  
Trial Master File Documents  
• Clinimark Control # B3000- 000-003 – Adverse Events and Protocol Deviation Reporting System  
• Clinimark Control # F2000- 001-029 - Device Deficiency Form  
• Clinimark Control #  F2000- 001-016 - Device Accountability Form  
• Clinimark Control # F2000- 001-015 - Delegation of Authority  
• Clinimark Control # F2000- 001-[ADDRESS_1001234] Disclosure  
• Clinimark Control # F2000- 001-022 – Investigator’s Certification Stateme nt 
• Clinimark Control # F2000- 001-[ADDRESS_1001235] Enrollment Log  
• Clinimark Control # F2000- 001-027 - Site Personnel Training Log 
• Clinimark Control # F2000- 001-033 - Site Visit/ Monitoring Log 
• Clinimark Control # F2000- 001-034 - Data Clarification Form  
• Clinima rk Control # F2000- 001-037 - Protocol Deviation Log 
• Clinimark Control # F2000- 001-038 - Adverse Events Log  
• Clinimark Control # F2000- 001-042 - Adverse Event CRF  
• Clinimark Control # F2000- 001-043 - Protocol Deviation Form  
• Clinimark Control # F2000- 001-[ADDRESS_1001236] Screening Log  
• Clinimark Control # F2000- 001-052 - Device Deficiency Log  
• Communications  
Current revision of documents applies.  
 
Amendments to the Clinical Investigation Plan  
Vital [LOCATION_003] or study site may need to make protocol changes during the study. Such amendments will be 
documented, reviewed and changes will be submitted to Vital [LOCATION_003] for first approval, then to the IRB for approval. 
Vital [LOCATION_003] and the study site will make a decision regarding t he continuation of subject enrollment during this 
period. The study site may proceed with the amendment upon receipt of IRB approval.  
 
Deviations from the Clinical Investigation Plan  
Investigators are not allowed to deviate from the Clinical Investigation Plan  (CIP) except under emergency 
circumstances. Deviations from the CIP to protect the rights, safety and well -being of human subjects may proceed 
without prior approval of the sponsor and the IRB. Such deviations shall be documented and reported to the 
spons or and the IRB as soon as possible and within [ADDRESS_1001237]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   19   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Device Accountability  
A Device Accountability Log will be maintained for the sponsor’s equipment documenting date of receipt, 
description of device (including model#, lot#, serial number or unique code, and quantity)  and date of return for  
used and unused product.  Device usage will be recorded in the Case Report Form for each individual subject.  
 
Packaging and Labeling 
Research conducted for this study will utilize investigational devices and devices cleared through the 510k regulatory proc ess. Vital [LOCATION_003] is responsible for packaging and labeling of the investigational d evice for delivery to 
the study site. FDA cleared devices do not require special labelling. Investigational devices or its immediate package shall bear a label with the follow ing information: name [CONTACT_164307], packager or 
distributor,  and the quantity of contents if appropriate , along with  the following statement:  
“CAUTION - Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use.”  
 
The label or other labeling shall describe all relevant contraindications, hazards, adverse effects, interfering 
substances or devices, warnings, and precautions.  
 It is the I nvestigator’s responsibility to ensure the appropriate labeling is visible  and remains intact throughout the 
life of the study.  
 The Instructions for Use (IFUs) are provided as separate documents from this protocol.  
 
Storage and Accountability  
The site will store the investigational product. The storage area should be locked/secure d with access limited only 
to approved study staff.   
The site will record/track use of the investigational device by [CONTACT_20908]. Documentation should verify that 
the device use was in accordance with the approved protocol. Equipment Doc ument in the Case Report Form shall 
provide documentation of the devices used on the study participant(s).  
 
Statement of Compliance 
The study will be conducted in accordance with the Declaration of Helsinki, 21 CFR 50, and 21 CFR 812 for non -
significant risk device study investigations . The study will not commence until the approval has been received from 
the IRB.  
 
Reference Documents  
• IRB Approved Informed Consent for Study Title:  Vital [LOCATION_003] Respi[INVESTIGATOR_732800]# PR 
2019 -326 
• ISO [ZIP_CODE]- 2-61, first edition 2011- 04-01, applicable sections, Clause 50 and Annex EE.3 Medical electrical 
equipment — Part 2 -61: Particular requirements for basic safety and essential performance of pulse 
oximeter equipment  
• FDA Guidance Document  for Pulse Oximeters, March 4, 2013 
• World M edical Association Declaration o f Helsinki, Ethical Principles for Medical Research Involving 
Human Subjects  
• ISO [ZIP_CODE]:2011 Clinical investigation of medical devices for human subjects —  Good clinical practice  
• Clinimark Adverse Events R eporting Document B3000 -000-003 (current revision)  
 
Informed Consent Process  
• The Principal Investigator [INVESTIGATOR_732801]  
• Verify that the subject acknowledges ability to read English  
 
 
Clinimark  
[ADDRESS_1001238]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   20   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Instruct the subject to ask questions at any time during this process, especially about things they do not 
understand  
• Allow subject ample time to read the entire form and ask questions  
• Give a thorough description of the study and the subject’s involvement –  especially explain that they may 
withdraw from the study at any tim e 
• After the subject has read the form ask if they understand everything  
• Ask if they would like to take part in the study and if so explain that they may sign and date the for m 
• Once the su bject has signed and dated the informed consent, the P rincipal Investigator or authorized 
designee will sign and date the form  
• Give a copy of the informed consent to the subject  
• No procedure may be performed before the informed consent is signed by [CONTACT_732807] I nvestigator  or their designee uses a investigational device without obtaining informed consent, the 
Investigator shall report such use to Vital [LOCATION_003] and the reviewing IRB within [ADDRESS_1001239] his/her health during the test. The  subject  or legal guardians  of the subject may 
withdraw  the subject  from the study at any time. The subject may be withdrawn per the Procedure section 
below.   
 
A clinicia n will be present to monitor the subject at all times. Safety monitoring includes, SpO 2, pulse rate, 
respi[INVESTIGATOR_1487], direct observation and communication with the subject.  
 
Adverse Event Definitions  
The definitions for adverse event, adverse device effec t, serious adverse event, serious adverse device effect, 
unanticipated adverse device effect, and their classifications are provided below (ISO [ZIP_CODE], 21 CFR 812.3).  
• Adverse Device Effect (ADE):  Adverse event related to the use of an investigational medica l device 
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, installation, the operation, or any malfunction of the investigational medical device or from error use.  
• Adverse Event (AE): Any untoward medical occurrenc e, unintended disease or injury or any untoward 
clinical signs (including an abnormal laboratory finding) in subjects, users or other persons whether or not related to the investigational medical device or investigational procedure  
• Anticipated Serious Adverse Device Effects (ASADE):  ASADE is an effect which by [CONTACT_5942], 
incidence, severity or outcome has been identified in the risk analysis report.  
• Mild:  a mild adverse event is one in which the subject is aware of the event, but it is easily t olerated 
without intervention.  
• Moderate:  a moderate adverse event is one that causes sufficient discomfort to interfere with usual 
activities.  
• Serious Adverse Device Effect (SADE): adverse device effect that has resulted in any of the consequences characte ristic of a serious adverse event  
 
 
Clinimark  
[ADDRESS_1001240]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   21   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Serious Adverse Event (SAE):  a serious adverse event is an adverse event that results in death, 
inpatient hospi[INVESTIGATOR_059], severe or permanent disability, a life -threatening illness or injury, fetal 
distress, fetal death, a congenital abnormality, a birth defect, or medical or surgical intervention to 
prevent permanent impairment to body or structure.  
• Severe:  a severe adverse event is one that results in the inability to perform usual activities.  
• Unanticipated Adverse Device Effect (UADE):  serious adverse device effect which by [CONTACT_110039] n ature, 
incidence, severity or outcome has not been identified in the current version of the risk analysis 
report. 
 
 
Management of Adverse Event Reporting  
Should the subject experience an adverse or non- typi[INVESTIGATOR_164272], assessment of the situation is first in itiated  and a 
determination will be made of appropriate actions. The Medical Director and Princip al Investigator will be 
contact[CONTACT_264760]. Adverse Events are reported through standard Clinimark Procedures, IRB requirements 
and per  Vital [LOCATION_003]’ s SOPs.   
 Records of Adverse events will be recorded in the Case Report Form  
The following information will be obtained:  
• Type of effect (ADE, AE. ASADE, SADE, SAE, UADE)  
• Date of onset and resolution  
• Intensity (mild, moderate, severe)  
• Serious (yes/no)  
• Relat ionship to device (unknown, not related, possibly related, probably related, definitely related)  
• Anticipated (yes/no)  
• Treatment given and / or action taken (procedure stopped, withdrawn from study, no action)  
 
Reporting of Serious Adverse Events and / or U ADE  
All SAE’s, SADE, ASADE and UADE will be reported in writing to the Principal Investigator, Medical Director , Vital 
[LOCATION_003] and IRB as soon as possible and no later than [ADDRESS_1001241], the event shall be reported to the Principal Investigator,  Clinimark  
Medical Director, Vital [LOCATION_003] and IRB within 24hrs of knowledge of the event.  
 
Vital [LOCATION_003]  Records and Reports  
Records 21 CFR 812.140 (b) 4,5  
The following records shall be consolidated in one location and available for FDA inspection and copying:  
• The name [CONTACT_29774]  
• A brief explanation of why the device is not a significant risk device  
• The name [CONTACT_732812] I nvestigator  
• The name [CONTACT_29776]  
• A statement of the extent to which the good manufacturing practice regulation in part 820 will be followed in manufacturing the device  
• Any other information required by [CONTACT_8415]  
• Records concerning adverse device effects (whether anticipated or unanticipated) and complaints   
 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  
The sponsor shall prepare and submit the following complete , accurate, and ti mely reports.  
 
 
 
Clinimark  
[ADDRESS_1001242]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   22   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Unanticipated Adverse Device Effect  
A sponsor shall immediately conduct an evaluation of an unanticipated adverse device effect. The results of 
such evaluation shall be reported to the FDA, IRB and participating I nvestigators as soon as possible and not 
later than  [ADDRESS_1001243] yearly.  
 
Recall and device  
Vital [LOCATION_003] shall notify FDA and all reviewing IRB's of any request that an I nvestigator return, repair, or 
otherwise dispose of any units of a n investigational  device. Such notice shall occur within [ADDRESS_1001244] was made.  
 
Final Report  
Vital [LOCATION_003] shall submit a final report to the IRB with 6 months after termination or completion of the 
investigation.  
 
Informed consent  
Vital [LOCATION_003] shall submit to FDA a copy of any report by [CONTACT_1629] I nvestigator under paragraph (a)(5) of this section of 
use of a n investigational  device without obtaining informed consent, within 5 working days of receipt of notice 
of such use.  
 
Significant risk device determinations –  (does not apply to NSR studies)  
If an IRB determines that a device is a significant risk device, and Vital [LOCATION_003] had proposed that the IRB consider 
the device not to be a significant risk device, Vital [LOCATION_003] shall subm it to FDA a report of the IRB's determination 
within [ADDRESS_1001245] learns of the IRB's determination.  
 
Other  
Vital [LOCATION_003] shall, upon request by a reviewing IRB or FDA, provide accurate, complete, and current information 
about any aspe ct of the investigation.  
 
Investigators Records and Reporting  
Records 21 CFR 812.140 (a)(3)(i)  
The Investigator maintains records of each subject’s case history and exposure to the device and supporting 
data including signed and dated consent forms, heal th assessment form, and progress notes during the study. 
Records should show evidence that informed consent was signed and dated prior to the subject participating 
in the study.  
 
Reports 21 CFR 812.150 (a) 1,2,5,7  
The Investigator shall prepare and submit  the following complete, accurate, and timely reports:  
 
Unanticipated adverse device effects  
 
 
Clinimark  
[ADDRESS_1001246]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   23   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
The Investigator shall submit to Vital [LOCATION_003] and to the reviewing IRB a report of any unanticipated adverse 
device effect occurring during an investigation as soon as possible, but in no event later than [ADDRESS_1001247].  
 
Withdrawal of IRB approval  
The Investigator shall report to Vital [LOCATION_003], within 5 working days, a withdrawal of approval by [CONTACT_732808] I nvestigator's part of an investigation.  
 
 
Informed consent  
If an I nvestigator uses a device without obtaining informed consent, the I nvestigator shall report such use to 
Vital [LOCATION_003] and the reviewing IRB within [ADDRESS_1001248] officially withdraws from the study, the laboratory staff will document the reason for withdrawal 
in the case report  form.  
  
Participation in the study may also be stopped at any time by [CONTACT_941] P rincipal Investigator or by [CONTACT_941] S ub-Investigators 
or sponsor.  
• The subject’s failure to cooperate fully (as determined by [CONTACT_941] I nvestigator in his or her sole discretion) 
with the required conduct of this study  
• The subject’s development of an illness as determined by [CONTACT_941] I nvestigator in his or  her sole discretion  
• A determination by a Clinimark representative (in his or her sole discretion), for whatever cause, that the 
study should be discontinued  
• A determination by [CONTACT_136181] (in his or her sole discretion), for whatever cause, that the study s hould be 
discontinued  
 The collection of data for study subjects will cease in the following cases:  
• Subject completes all study requirements  
• Subject withdraw s consent  
• Investigator’s decision that it is in subject’s best interest to be discontinued from the study  
• Subject death  
• Adverse event other than death requiring withdrawal of the subject from the study  
• Determination that the subject was ineligible for the study.  
 There will not be any follow -up procedures for withdrawn or discontinued subjects required unless a follow -up is 
required a t the Investigator’s discretion . 
 
Consideration for early termination or suspension of the investigation is tied to unanticipated equipment failure or 
a decision by [CONTACT_348569]. Both Vital [LOCATION_003] and Clinimark reserve the right to discontinue the study at any 
time for administrative or other reasons. Written notice of study termination will be submitted to the I nvestigator 
in advance of such termination. Termination of a specific site can occur because of, but not limited to, inadequate 
data collection, low subject enrollment, or non -compliance with the protocol or other research requirements.  
 
 
 
Clinimark  
[ADDRESS_1001249]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   24   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Early termination results when the study is  closed prior to the end of the study. A study suspension is  a temporary 
postponement of the study activities related to enrollment. Both are possible for the study.  If the study is 
terminated or suspended, no additional enrollment will be allowed unless otherwise informed by [CONTACT_136181]. The 
current subjects will be fo llowed according to the protocol.  
 
If the study is terminated prematurely or suspended by [CONTACT_136181] /Investigator, Vital [LOCATION_003] /investigator will 
promptly inform the regulatory authorities (if required) of the termination and the reason(s). IRB/IECs will als o be 
promptly informed and provided with the reason(s) for termination or suspension by [CONTACT_732809] /Investigator. 
The Investigator will promptly inform the subjects and assure appropriate follow -up for the subject.  
 If the I nvestigator (or IRB/IEC) terminates or suspends the investigation the I nvestigator will promptly inform the 
institution (if required) and the IRB/ IEC and  provide a detailed written explanation of the termination or 
suspension. The I nvestigator will promptl y inform the subjects and assure appropriate therapy and follow -up for 
the subjects. Vital [LOCATION_003] will inform the regulatory authorities (if required).  
 
Withdrawal of IRB approval shall be reported to Vital [LOCATION_003] by [CONTACT_941] I nvestigator within 2 working days.  
 In case of early termination of the study, all study subjects should be followed until the resolution of any pending 
adverse event(s).  
 
Publication Policy  
The result s of this investigation will not  be submitted for publication.  
 
 
Clinimark  
[ADDRESS_1001250]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE:   Vital [LOCATION_003] Respi[INVESTIGATOR_732760]# PR 2019 -326 
Principal Investigator: [INVESTIGATOR_136170], MD  — Site ID # 001  DOCUMENT NUMBER  
PR 2019 -326 
SHEET   25   of   25 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Attachment A -  Protocol Signatu re Page  
 
Protocol No. PR [ADDRESS_1001251] read this protocol, I understand it, and I will work according to 
this protocol and to the ethical principles stated in accordance with the Declaration of Helsinki, 21 C FR 50, and 21 
CFR 812: or the applicable laws and regulations of the country of the study site for which I am responsible, 
whichever provides the greater protection of the individual  participant . 
• Ensuring informed consent of  each subject is obtained prior to the start of any study procedure  
• Ensuring the investigation is conducted according to the Clinical Investigation Plan,  
• Personally conducting or supervising the investigation,  
• Protecting the rights, safety, and welfare of participants,  
• Preparing and maintaining adequate, current, and complete case histories or records,  
• Retaining records for two years following the date the marketing application is approved or withdrawn,  
• Furnishing the required reports to the sponsor, including reports of adverse events and study completion,  
• Providing timely reports to the IRB, including reports of changes in the research activity needed to avoid 
immediate hazards to participants, unanticipated problems involving risks to participa nts or  others, 
including adverse events to the extent required by [CONTACT_1201],  
• Ensuring that changes are not implemented without prospective IRB approval, unless required to 
eliminate immediate hazard to participants,  
• Complying with all FDA test article requir ements,  
• Adequately maintaining control of test articles, including appropriate tracking documentation for test articles to the extent that such control and documentation are not centrally administered,  
• Supervising the use and disposition of the test articl e, 
• Disclosing relevant financial information,  
• Ensuring that all associates, colleagues, and employees assisting in the conduct of the investigation(s) are informed about their obligations in meeting the above commitment s, and  
• An Investigator shall, upon re quest by a reviewing IRB or FDA, provide accurate, complete, and current 
information about any aspect of the investigation.  
 
  26 APR 2019  
Signature [CONTACT_164310], MD    
Investigator Name (print or type)    
Principal Investigator    
[INVESTIGATOR_348552], CO [LOCATION_003]    
Location of Facility (City, State, Country)    
